Treatment News : Avexa Shelves Development of HIV Drug Apricitabine

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 10, 2010

Avexa Shelves Development of HIV Drug Apricitabine

Avexa Limited has decided to end its development of apricitabine (ATC), a nucleoside reverse transcriptase inhibitor (NRTI), according to a May 10 announcement by the company. The decision was reached after an ATC Phase III study was closed and, according to Avexa, because of unsuccessful efforts to partner with other pharmaceutical companies to continue developing the drug.

Apricitabine was originally developed by BioChem Pharma (where it was called BCH10618), first sold to Shire Pharmaceuticals (where the drug was called SPD754) and then sold to Avexa. The NRTI’s chemical structure was similar to that of lamivudine (found in Epivir, Combivir and Trizivir) and emtricitabine (found in Emtriva, Truvada and Atripla), but with the advantage of being active against HIV resistant to lamivudine and emtricitabine.

The premature closing of ATC’s Phase III clinical trial was announced October 2, 2009. The company didn’t share the reason why it terminated the study before it completed the planned 48-week follow-up period. Avexa did, however, say that it planned to analyze the data and to explore partnership options with other pharmaceutical companies to potentially continue developing ATC.

“The board is of the view that Avexa has exhausted all possible avenues to complete a global licensing transaction for ATC,” the company wrote in its May 10 statement. “However, [Avexa] intends to continue discussions with smaller regionally focused companies who have expressed an interest in a regional licensing transaction for ATC.”

Avexa cited a number of reasons for the lack of interest among potential global pharmaceutical partners. First, the time and capital required to secure regulatory approval for ATC, in various countries, may be too large of a commitment. Second, ATC’s required dosage may be too high when used in combination with certain approved HIV drugs, making it difficult to be combined into one pill with those drugs. Third, it may be difficult to determine ATC’s effectiveness when used in combination with a number of new active drugs on the market, which will likely mask the level of ATC’s activity

Search: apricitabine, ATC, Avexa, BIoChem, Shire, lamivudine, emtricitabine

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.